How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment

Bone Marrow Transplantation

Volumn 41, Issue 1, 2008, Pages 23-26

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; LITHIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ARTICLE; CD34 SELECTION; CLINICAL TRIAL; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOPOIESIS; LYMPHOCYTE COUNT; NEUTROPHILIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRUCTURAL HOMOLOGY; UPREGULATION;

ANIMALS; ANTIGENS, CD26; CHEMOKINE CXCL12; GLYCOGEN SYNTHASE KINASE 3; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LITHIUM COMPOUNDS; NEUTROPHILS; PHOSPHORYLATION; PYRAZINES; RECEPTORS, CXCR4; TRIAZOLES;

EID: 38349074045     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705872     Document Type: Article

References (31)

1. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940.
2. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry 2007; 68: 380-383.
3. Murphy DL, Goodwin FK, Bunney Jr WE. Leukocytosis during lithium treatment. Am J Psychiatry 1971; 127: 1559-1561.
4. Tisman G, Herbert V, Rosenblatt S. Evidence that lithium induces human granulocyte proliferation: Elevated serum vitamin B 12 binding capacity in vivo and granulocyte colony proliferation in vitro. Br J Haematol 1973; 24: 767-771.
5. Joyce RA. Sequential effects of lithium on haematopoiesis. Br J Haematol 1984; 56: 307-321.
6. Canales MA, Arrieta R, Hernandez-Garcia C, Bustos JG, Aguado MJ, Hernandez-Navarro F. A single apheresis to achieve a high number of peripheral blood CD34 + cells in a lithium-treated. patient with acute myeloid leukaemia. Bone Marrow Transplant 1999; 23: 305.
7. Ballin A, Lehman D, Sirota P, Litvinjuk U, Meytes D. Increased number of peripheral blood CD34 + cells in lithium-treated patients. Br J Haematol 1998; 100: 219-221.
8. Forde JE, Dale TC: GlyAogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007; 64: 1930-1944.
9. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: Implication in the treatment of bipolar disorder. Biol Psychiatry 2007; 61: 216-222.
10. Shaltiel G, Chen G, Manji HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007; 7: 22-26.
11. Flugel D, Gorlach A, Michiels C, Kietzmann T. Glycogen synthase kinase-3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 2007; 27: 3253-3265.
12. Wiesener MS, Maxwell PH. HIF and oxygen sensing; as important to life as the air we breathe? Ann Med 2003; 35: 183-190.
13. Jensen RL, Ragel BT, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (NTGF) secretion and tumor growth in malignant gliomas. J Neurooncol 2006; 78: 233-247.
14. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431-5436.
15. Heissig B, Ohki Y, Sato Y, Rafii S, Werb Z, Hattori K. A role for niches in hematopoietic cell development. Hematology 2005; 10: 247-253.
16. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/ CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007; 1106: 1-19.
17. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
18. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR. Clinical importance dnd therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007; 28: 123-131.
19. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221-1232.
20. Liu YL, Yu JM, Song XR, Wang XW, Xing LG, Gao BB. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 2006; 5 1320-1326.
21. Tabatabai G, Frank B, Mohle R, Weller M, Wick W. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 2006; 129 (Part 9): 2426-2435.
22. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Klenman ME et al. Progenitor cell trafficking is regulated by hypoxie gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10 858-864.
23. Dewhirst MW, Cao Y, Li CY, Moeller B. Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 2007; 83: 249-255.
24. Fulda,S, Debatin KM. EHF-1-regulated glucose metabolism a key to apoptosis resistance? Cell Cycle 1007; 6: 790-792.
25. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006; 238: 30-41.
26. Pore N, Maity A. The chemokine receptor CXCR4: A homing device for hypoxic cancer cells? Cancer Biol Ther 2006; 5: 1563-1565.
27. Duke-Cohan JS, Morimoto C, Rocker JA, Schlossman SF. Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J Immunol 1996; 156: 1714-1721.
28. Christopherson II KW, Uralil SE, Porecha NK, Zabriskie RC, Kidd SM, Ramin SM. G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38- human cord blood hematopoietic cells. Exp Hematol 2006; 34: 1060-1068.
29. Christopherson II KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004; 305: 1000-1003.
30. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
31. Focosi D, Kast RE, Petrini M. Gliptins. Lancet 2007; 369: 269-270.